¹H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis

C A Davie, G J Barker, A J Thompson, P S Tofts, W I McDonald, D H Miller

Abstract

Objectives—To test the hypothesis that irrecoverable neurological deficit in multiple sclerosis is associated with axonal loss.

Methods—¹H magnetic resonance spectroscopy (MRS) was carried out in a group of patients with clinically definite multiple sclerosis (n=31).

Using this technique, the apparent concentration of NA ([NA] the sum of N-acetyl aspartate (NAA), a neuronal marker, and N-acetylaspartylglutamate has been compared in four groups of patients with multiple sclerosis classified as relapsing-remitting, secondary progressive, primary progressive, benign, and a control group.

Results—In the patients with relapsing-remitting disease (n=9) there was a highly significant reduction of apparent NA (median 8.73 mM, range 6.86 mM–10.74 mM, $P=0.0008$) from an area of high signal compared with the control group (median 11.97 mM, range 10.55 mM–14.5 mM). In the patients with secondary progressive disease (n=10), there was again a highly significant reduction of apparent NA (median 7.82 mM, range 3.5 mM–10.3 mM, $P=0.0003$) from an area of high signal compared with the control group. In the patients with primary progressive disease (n=6) there was once again a highly significant reduction of apparent NA (median 8.83 mM, range 6.95 mM–9.89 mM, $P<0.002$) from an area of high signal compared with the control group. In the patients with benign disease, however, there was no significant difference in the apparent NA (median 10.5 mM, range 8.53 mM–12.8 mM, $P>0.05$) from an area of high signal compared with the control group. In the patients with benign disease (n=5) there was also no significant difference in the apparent NA (median 10.74 mM, range 8.58 mM–13.4 mM, $P>0.3$) from an area of normal appearing white matter compared with the control group. In the patients with primary progressive disease, however, there was a significant reduction of apparent NA from an area of normal appearing white matter (median 8.78 mM, range 8.7 mM–12.38 mM, $P<0.025$) compared with the control group.

There was a significant inverse correlation between [NA] from lesions in the

patients with multiple sclerosis and disability as measured on the Kurtzke expanded disability scale score ($r=-0.364$, $0.05>P>0.02$).

Conclusion—These findings support the hypothesis that axonal loss is important in the development of disability in multiple sclerosis. They also provide evidence for axonal loss in normal appearing white matter in patients with primary progressive disease.

(*J Neurol Neurosurg Psychiatry* 1997;63:736–742)

Keywords: multiple sclerosis; N-acetyl aspartate; disability

It is well recognised that the clinical course of multiple sclerosis may follow various patterns. Most patients have a relapsing, remitting course at onset¹ although after a variable interval many will develop progressive disability on a background of superadded relapses.² In about 30% of patients however, the disease adopts a benign course in which minimal disability is seen after 10 years from symptom onset.³ In 10 to 15% of patients with multiple sclerosis the disease process is progressive from onset (one year progressive disease). These patients tend to be male, are older at the onset of symptoms, and often present with a spastic paraparesis.² Magnetic resonance imaging studies in these patient groups^{2–4} have shown important differences in the distribution, size, and frequency of lesion development together with differing degrees of blood-brain barrier breakdown as evidenced by the presence of enhancement after the administration of gadolinium-DTPA. However, to date there has been poor correlation between the degree of disability in the various patient subgroups and lesion load measured from conventional MRI.^{5–6}

Although conventional MRI is sensitive in detecting the lesions of multiple sclerosis, it disclosed neither demyelination nor axon loss itself. Proton magnetic resonance spectroscopy (MRS) is a nuclear magnetic resonance technique which has the potential to detect axon loss non-invasively during life. The normal proton spectrum is dominated by N-acetyl derived groups (NA; the sum of N-acetyl aspartate (NAA) and N-acetylaspartylglutamate).⁷ The predominant component of the NA peak is NAA, an amino acid of unknown function which has been shown in experimental studies on neonatal rats to be contained almost

NMR Research Unit,
Institute of Neurology,
Queen Square, London
WC1N 3BG, UK

CA Davie
GJ Barker
AJ Thompson
PS Tofts
WI McDonald
DH Miller

Correspondence to:
Dr CA Davie, NMR
Research Unit, Institute of
Neurology, Queen Square,
London WC1N 3BG, UK.

Received 31 January 1997
Accepted 11 April 1997

exclusively within neurons.⁸ A loss of neurons (cell bodies and axons) would be predicted to cause a persistent reduction in the concentration of NAA. That this is so has been shown in diseases characterised by neuronal loss.⁹⁻¹² To test the hypothesis that irrecoverable neurological deficit in multiple sclerosis is associated with axon loss, the apparent concentration of NA has been compared in four groups of patients classified as relapsing-remitting, secondary progressive, primary progressive, and benign.

Materials and methods

PATIENTS

Patients with clinically definite multiple sclerosis¹³ were recruited from the National Hospital for Neurology and Neurosurgery. The study was approved by the joint ethics committee at the Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London. Informed consent was obtained from all patients before each study.

The patient groups were defined as follows:

(1) Relapsing-remitting disease (n=9): these patients had a history of relapses and remission without gradual deterioration, excluding benign cases. They had a median age of 31 (range 26-49 years) and a median disease duration of three (range 1-12 years). The median Kurtzke expanded disability status score (EDSS) was 3.5 (range 2.0-5.5)

(2) Benign disease (n=9): these patients had relapsing-remitting disease of at least 10 years of duration of disease with a disability on the Kurtzke EDSS ≤ 3.0 . They had a median age of 45 (range 39-63) years and a median disease duration of 20 (range 10-35) years. The median Kurtzke EDSS score was 2.5 (range 1.0-3.0)

(3) Secondary progressive disease (n=10): these were patients presenting with a relapsing-remitting course with evidence of progressive deterioration for at least six months with or without superimposed relapses. They had a median age of 46 (range 21-55) years and a median disease duration of 13.5 (range 5-25) years. The median Kurtzke EDSS was 7.0 (range 4.0-8.0).

(4) Primary progressive disease (n=8): these patients had progressive deterioration from symptom onset without any relapses or remissions. They had a median age of 42 (range 37-47) and a median disease duration of 4.5 (range 1.5-19) years. The median Kurtzke EDSS was 6.0 (range 5.0-7.5)

Nine healthy controls were also studied (median age 40 (range 18-57) years). The controls were recruited from members of staff at the National Hospital for Neurology.

MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY

Brain MRI and MRS were performed with a 1.5 T GE Signa whole body scanner using a standard quadrature head coil. The study commenced with a T2 weighted fast spin echo imaging sequence (TR 3000 ms, TE_f 80 ms) (5 mm slices with 2.5 mm gap, 256×256 matrix, echo train length 8). After imaging, a volume

of interest ranging between 3.5 ml and 6 ml was prescribed which in the patient group incorporated a chronic high signal lesion or an area of normal appearing white matter.

Lesions were determined to be chronic if they were unchanged on imaging over a period of six months or greater. Large lesions were chosen to minimise partial volume effects. If a sufficiently large enough lesion could not be identified on imaging then spectra were collected from normal appearing white matter alone. In several of the patients it was not possible to collect spectra from an area of high signal and normal appearing white matter because of time constraints and patient compliance. An MR image of the voxel was then obtained to ensure accurate localisation. Water suppressed ¹H spectra were obtained using a STEAM sequence.^{14,15} Acquisition indices were TR 2000 ms, TM 12 ms, and TE 135 ms; 256 averages were collected using an eight step phase cycle in about nine minutes; 1024 points were collected, with a spectral width of 750 Hz. Shimming to a line width of about 1.5 Hz, and water suppression were reoptimised for each new location. In the control group, spectra were collected from an area of periventricular white matter similar in volume and site to the lesions studied in the multiple sclerosis groups.

Data processing included 1.5 Hz line broadening for filtering, Fourier transformation, and zero order phase correction. No baseline correction was applied. Peak areas were determined using a line fitting programme ("SA / GE", GE Milwaukee WI, USA). Peaks were fitted to a gaussian line shape using a Marquardt fitting procedure. Absolute concentrations for the metabolites were calculated using the fully relaxed water signal as an internal standard of reference.¹⁶ Metabolite concentrations [met] were calculated from the equation

$$[\text{Met}] = [\text{H}_2\text{O}] \times 2/\text{PI} \times \text{T1}_{\text{corr}} \times \text{T2}_{\text{corr}} \times \text{S}_0_{\text{MET}} / \text{S}_0_{\text{H}_2\text{O}} \times 1/2[\text{R}]$$

where S_0_{MET} and $\text{S}_0_{\text{H}_2\text{O}}$ denote the signal intensities for metabolites and water respectively, $[\text{H}_2\text{O}]$ is the brain water concentration from the volume of interest. The water concentration from the voxel of interest was calculated by comparing the signal intensity from the proton density images in the putamen with the region of interest in the hemispheric white matter. The putamen was chosen as this region of the basal ganglia is not affected by deposition of heavy metal in healthy controls.¹⁷ Furthermore, a recent study by Grimaud *et al*¹⁸ has shown no evidence of hypointensity on T2 weighted images to suggest increased deposition of heavy metals in the putamen of patients with multiple sclerosis.

The water concentration of normal appearing grey matter has been taken as 45.5 M.¹⁹ In the control groups the concentration of water in white matter has been taken as 39.75 M.¹⁹ T1_{corr} and T2_{corr} are T1 and T2 correction values based on published T1 and T2 times from parietal white matter for the metabolites

Figure 1 ^1H MRS (TE 135 ms TR 2000 ms, volume 4 ml) from periventricular parietal white matter in a healthy 40 year old control).

Figure 2 ^1H MRS (TE 135 ms TR 2000 ms, volume 5ml) from a chronic parietal white matter lesion in a patient with relapsing-remitting multiple sclerosis (patient 12) showing reduction of [NA].

studied.²⁰ As absolute T1 and T2 values were not calculated for patients and controls, the term apparent concentration is used. 2/PI denotes the proton index and refers to the number of protons in each metabolite (three for NAA, three for creatine, nine for choline). The value of 2 represents the two protons in H_2O . $R = R_{\text{metabolite}} - R_{\text{water}}$ and accounts for different receiver attenuator settings.

Statistical analysis was performed with a Mann-Whitney confidence interval and test. Results are expressed as a median value together with the range and P value. A Spearman's rank correlation test was also used and results are expressed as an r value together with levels of significance.

Results

MRS LESIONS

Figure 1 shows a spectrum from a healthy control. Metabolic assignments are based on published data.²¹

All patients in the relapsing-remitting and secondary progressive groups had lesions large enough to be studied with single voxel spectroscopy. In the benign group six patients had lesions large enough to study with MRS. Similarly, in the primary progressive group, six patients had at least one lesion of sufficient size to study with spectroscopy.

Relapsing-remitting patients

In the patients with multiple sclerosis with relapsing remitting disease ($n=9$) there was a highly significant reduction of apparent NA (median 8.73 mM, range 6.86 mM–10.74 mM, $P=0.0008$) from an area of high signal compared with the control group (median 11.97 mM, range 10.55–14.5 mM). The apparent creatine concentration in the same

group from an area of high signal was reduced (median 8.3 mM, range 7.0 mM–12.1 mM, $P=0.29$) compared with controls (median 9.05 mM, range 8.1 mM–11.7 mM) although this did not reach significance. There was no significant difference in the apparent choline concentration between the relapsing-remitting lesion group (median 1.73 mM, range 1.27 mM–2.5 mM, $P=1$) and controls (median 1.66 mM, range 1.29 mM–1.9 mM) (fig 2).

Secondary progressive patients

In the patients with secondary progressive disease ($n=10$), there was again a highly significant reduction of apparent NA (median 7.82 mM, range 3.5 mM–10.3 mM, $P=0.0003$) from an area of high signal compared with the control group. The apparent creatine concentration in the same group from an area of high signal was reduced (median 7.89 mM, range 4.83 mM–10.3 mM, $P=0.1$) though again this did not reach significance. There was no significant difference in the apparent choline concentration between the secondary progressive lesion group (median 1.78 mM, range 1.36 mM–2.18 mM, $P=0.48$) and controls (fig 3).

Primary progressive patients

In the patients with multiple sclerosis with primary progressive disease ($n=6$) there was once again a highly significant reduction of apparent NA (median 8.83 mM, range 6.95 mM–9.89 mM, $p<0.002$) from an area of high signal compared with the control group. The apparent creatine concentration in the same group from an area of high signal was reduced (median 7.39 mM, range 6.47 mM–12.4 mM, $P>0.08$) although again this did not reach significance. There was no significant difference

Figure 3 ¹H MRS (TE 135 ms TR 2000 ms, volume 4.1 ml) from a chronic parietal white matter lesion in a patient with secondary progressive multiple sclerosis (patient 19) showing reduction of [NA].

in the apparent choline concentration between the primary progressive lesion group (median 2.0 mM, range 1.3 mM–2.28 mM, $P>0.20$) and controls (fig 4).

Benign patients

In the patients with benign disease there was no significant difference in the apparent NA (median 10.5 mM, range 8.53 mM–12.8 mM,

Figure 4 ¹H MRS (TE 135 ms TR 2000 ms, volume 5.3 ml) from a chronic parietal white matter lesion in a patient with primary progressive multiple sclerosis (patient 30) showing reduction of [NA].

Figure 5 ¹H MRS (TE 135 ms TR 2000 ms, volume 4.4 ml) from a chronic parietal white matter lesion in a patient with benign multiple sclerosis (patient 6) showing a relative preservation of [NA].

$P>0.05$) from an area of high signal compared with the control group. The apparent creatine concentration in the same group from an area of high signal was reduced (median 7.7 mM, range 5.96 mM–11 mM, $P>0.4$) although this did not reach significance. There was no significant difference in the apparent choline concentration between the benign lesion group (median 1.75 mM, range 1.08 mM–2.25 mM, $P>0.34$) and controls (fig 5).

MRS NORMAL APPEARING WHITE MATTER

Primary progressive patients

In the patients with primary progressive multiple sclerosis there was a significant reduction of apparent NA from an area of normal appearing white matter (median 8.78 mM, range 8.7 mM–12.38 mM, $P<0.025$) compared with the control group (fig 6). The apparent creatine concentration in the primary progressive group from an area of normal appearing white matter (median 8.9 mM, range 6.46 mM–9.49 mM, $P>0.5$) did not differ from the control group. There was no significant difference in the apparent choline concentration from normal appearing white matter in the primary progressive lesion group (median 1.44 mM, range 0.96 mM–2.53 mM, $P>0.14$) and controls.

Benign patients

In the patients with multiple sclerosis with benign disease ($n=5$), there was no significant difference in the apparent NA (median 10.74 mM, range 8.58 mM–13.4 mM, $P>0.3$) from an area of normal appearing white matter compared with the control group. The apparent creatine concentration in the benign group from an area of normal appearing white matter (median 9.15 mM, range 8.68 mM–9.76 mM,

Figure 6 ^1H MRS (TE 135 ms TR 2000 ms, volume 4.8 ml) from an area of normal appearing white matter in a patient with primary progressive multiple sclerosis (patient 30) showing reduction of [NA].

$P > 0.9$) did not differ from the control group. There was no significant difference in the apparent choline concentration between the benign lesion group (median 1.82 mM, range 1.72 mM–2.28 mM, $P > 0.12$) and controls.

It was not possible to collect spectroscopic data from normal appearing white matter in

Duration of disease, Kurtzke EDSS, and [NA] in the multiple sclerosis lesion subgroups

	Duration of disease (y)	EDSS	[NA]
Benign patients:			
1	20	3.0	11.45
2	19	2.0	12.8
3	14	2.0	9.01
4	25	2.5	9.9
5	15	2.5	8.53
6	29	3.0	10.5
Relapsing-remitting patients:			
7	4	5.0	9.67
8	1	2.0	10.74
9	1.5	3.0	7.12
10	5	2.5	10.14
11	12	5.0	8.14
12	3	3.5	8.4
13	1.5	2.0	10.25
14	1	2.0	6.9
15	1	3.5	8.73
One year progressive patients:			
16	14	4.0	10.3
17	7	5.5	3.5
18	20	7.5	9.97
19	20	7.5	6.97
20	13	8.0	5.4
21	25	7.0	7.22
22	7	4.5	8.47
23	24	4.0	7.43
24	7	7.5	10.07
25	5	7.5	8.2
Two year progressive patients:			
26	8	7.5	9.89
27	3	6.0	9.02
28	4	5.0	9.84
29	1.5	5.5	6.95
30	4	6.0	7.37
31	9	6.0	8.64

Figure 7 [NA] from lesions v Kurtzke EDSS in patients with relapsing-remitting disease.

the patients with relapsing-remitting and secondary progressive disease.

There was a small significant inverse correlation between [NA] from lesions in all patients with multiple sclerosis taken collectively and disability as measured on the Kurtzke EDSS ($r = -0.364$, $0.05 > P > 0.02$).

Discussion

There are three major findings in this study. The first is the relative preservation of [NA] from lesions in the patients with benign multiple sclerosis compared with [NA] from lesions in the primary progressive, secondary progressive, relapsing-remitting patients, and normal appearing white matter from the control group. The second finding of note is a small but nevertheless significant correlation between the reduction of [NA] from a multiple sclerosis lesion and the degree of disability measured on the Kurtzke EDSS. Finally, this study has shown a reduction of [NA] from normal appearing white matter in the primary progressive group of patients with multiple sclerosis compared with the preservation of [NA] from normal appearing white matter in the benign group of patients with multiple sclerosis and healthy controls.

[NA] IN MULTIPLE SCLEROSIS LESIONS

Lesions from the patient groups with progressive and relapsing-remitting multiple sclerosis

Figure 8 Kurtzke EDSS v [NA] in patients in all subgroups of multiple sclerosis.

showed a significant reduction in the median [NA]. The demonstration of a reduced [NA] in these patient groups is in keeping with previous studies on multiple sclerosis lesions, in which a reduction in the NAA/creatinine ratio²²⁻²⁴ or an absolute reduction of [NA] has been found.¹⁶⁻²⁵

However, an original finding in the present study is the relative preservation of [NA] from lesions in patients with multiple sclerosis with benign disease. The incidence of benign multiple sclerosis varies in different series from between 15% and 40%.³⁻²⁶⁻²⁷ The pathophysiological mechanisms that lead to a benign course are not fully understood. Studies with MRI in the brain⁶ or spinal cord²⁸ have shown little or no relation between disability and lesion load.

Given that the principal component of NA is N acetyl aspartate, an amino acid almost exclusively localised within neurons and their processes,⁸ the relative preservation of [NA] from lesions in the benign group may reflect a relative preservation of axons in these lesions. It may be that the less pronounced initiating inflammatory event in benign multiple sclerosis produces less axonal disruption and a preserved capacity for axonal repair.

The patients in the primary progressive and secondary progressive groups had a significantly higher median Kurtzke EDSS than the patients in the benign group. It is perhaps surprising that the relapsing-remitting group showed such a large reduction in the median [NA] given that several of the patients in this group had minimal disability. There is, however, a tendency for the patients with minimal disability in this group to have the highest [NA] (fig 7). It is probable that some of the patients in this group will have a benign form of the disease over time and thus would be expected to have a preservation of NA in lesions. An obvious explanation for this finding is that the patients in the relapsing-remitting group who had higher [NA] tended towards a shorter duration of disease (table).

CORRELATION BETWEEN THE REDUCTION OF [NA] FROM A MULTIPLE SCLEROSIS LESION AND THE DEGREE OF DISABILITY MEASURED ON THE KURTZKE EDSS

This study has also shown a weak correlation between the reduction of [NA] from multiple sclerosis lesions and increased disability as measured on the Kurtzke EDSS (fig 8). That only a modest correlation was found is not surprising. Previous investigators have failed to show a correlation between a reduction in NAA and disability,²⁹ probably because, as in the present study, lesions and normal appearing white matter in the periventricular areas were examined which are not clinically eloquent³⁰ except in relation to cognitive function.³¹⁻³² A study described previously by our group concentrated on an area of the brain that was clinically eloquent and showed a stronger correlation between a reduction of NAA and the Kurtzke EDSS.²⁵ Furthermore, a spectroscopic study of acute symptomatic lesions showed a strong negative correlation between reduction of NAA and disability.³³

REDUCTION OF [NA] FROM NORMAL APPEARING WHITE MATTER IN THE PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

The other finding of note in this study was the significant reduction of [NA] in normal appearing white matter in patients with primary progressive multiple sclerosis (fig 6) compared with normal appearing white matter from patients with benign multiple sclerosis and white matter from healthy controls. Other studies have noted a qualitative reduction in the NAA:creatinine ratio from normal appearing white matter in patients with multiple sclerosis.²⁴⁻³⁴ Such a reduction is likely to reflect microscopical abnormalities, which have been documented in pathological studies.³⁵ A diffuse pathological process in primary progressive multiple sclerosis may explain the tendency towards increased disability in these patients despite the relative lack of visible lesions on MRI.²

OTHER FINDINGS

In the present study there was a tendency for the creatine concentration to be reduced in lesions from all multiple sclerosis groups although this was not significant. This is in keeping with a recent postmortem study by Davies *et al*³⁶ which showed an absolute reduction of both NA and creatine from multiple sclerosis lesions studied 48 hours after death whereas areas of normal appearing white matter studied showed normal metabolite concentrations. There was no significant difference between the creatine concentration from normal appearing white matter in the benign and primary progressive patients compared with controls.

IMPLICATIONS FOR FUTURE STUDIES

The present study has shown a reduction in [NA] from lesions in those subgroups of patients with a greater degree of clinical disability. By contrast, patients with benign multiple sclerosis showed a preservation of NA from lesions and normal appearing white matter indicating a less destructive pathological process in this patient group. Patients with primary progressive multiple sclerosis showed, in addition to a low [NA] from lesions, a reduction of [NA] from normal appearing white matter, perhaps indicating a more diffuse pathological process in this subgroup.

Some of the patients in the relapsing-remitting group who had minimal disability showed a preservation of [NA]. These patients tended to have a shorter duration of disease. It therefore cannot be concluded that spectroscopy of lesions is predictive of clinical outcome in patients with relapsing-remitting multiple sclerosis. The findings from the present study, however, are of enough interest to pursue this issue further. With the advent of β -interferon, an agent that reduces the frequency of evidence of new disease activity in early relapsing-remitting multiple sclerosis³⁷⁻³⁸ it has become more necessary to find a reliable means of predicting clinical outcome at an early stage of the disease. A future longitudinal spectroscopic trial of patients with relapsing-remitting

disease with minimal clinical disability and a wide range of duration of disease should provide the answer to whether spectroscopy could be a useful tool for this purpose.

This work has been generously supported by a grant from the Multiple Sclerosis Society of Great Britain and Northern Ireland. Software for spectroscopic analysis was provided by General Electric (GE Milwaukee, WI, USA).

- Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, *et al.* Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. *Neurology* 1992;42:60–3.
- Thompson AJ, Kermode AG, Wicks D, MacManus D, Kendall BE, Kingsley DPE, *et al.* Major differences in the dynamics of primary and secondary progressive multiple sclerosis. *Ann Neurol* 1991;29:53–62.
- McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases within three years of onset and followed up until the tenth year or more of the disease. *Brain* 1961;84:186–203.
- Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. The benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. *J Neurol Neurosurg Psychiatry* 1994;57:1070–2.
- Li DKB, Mayo J, Fache S, Robertson W, Kastrukoff LF, Oger J, *et al.* Lack of correlation between clinical manifestations and lesions of MS seen by NMR [abstract]. *Neurology* 1984;34(suppl 1):S136.
- Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, *et al.* Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. *BMJ* 1990;300:631–4.
- Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in ¹H-NMR spectroscopic studies of brain. *Neurosci Biobehav Rev* 1989;13:23–31.
- Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. *J Neurosci* 1993;13:981–9.
- Davie CA, Wenning GK, Barker GJ, Tofts PS, Quinn N, Marsden CD, *et al.* Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. *Ann Neurol* 1995;37:204–10.
- Gideon P, Henriksen O, Sperling B, Permlle C, Skyhøj Olsen T, Jørgensen HS, *et al.* Early time course of N acetylaspargate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. *Stroke* 1992;23:1566–72.
- Van der Knaap MS, Van der Grond J, Luyten PR, Hollander JA, Nauta JJP, Valk J. ¹H and ³¹P magnetic resonance spectroscopy of brain degenerative cerebral disorders. *Ann Neurol* 1992;31:202–11.
- Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, *et al.* Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. *Radiology* 1993;188:119–24.
- Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, *et al.* New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol* 1983;13:227–31.
- Frahm J, Merboldt KD, Hancic W. Localised proton spectroscopy using stimulated echoes. *J Magn Reson* 1987;72:502–8.
- Frahm J, Michaelis T, Bruhn H, Gyngell ML, Merboldt KD, Hancic W. Improvements in localised proton NMR spectroscopy of human brain, water suppression, short echo times and 1ml resolution. *J Magn Reson* 1990;290:464–73.
- Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsen HBW. In vivo quantification of brain metabolites by ¹H-MRS using water as an internal standard. *Magn Reson Imaging* 1993;11:107–18.
- Olanow CW. Magnetic resonance imaging in parkinsonism. *Neurol Clin* 1992;10:405–20.
- Grimaud J, Miller J, Thorpe JW, Moseley IF, McDonald WI, Miller DH. Signal intensity on MRI of basal ganglia in multiple sclerosis. *J Neurol Neurosurg Psychiatry* 1995;59:306–8.
- Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing leukoencephalitis. II. Chemical studies including abnormal myelin and an abnormal ganglioside pattern. *J Neuropathol Exp Neurol* 1966;25:582–97.
- Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hancic W, Sauter R. Localised proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. *Magn Reson Med* 1989;11:47–63.
- Behar KL, Ogino T. Assignment of resonances in the ¹H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. *Magn Reson Med* 1991;17:285–303.
- Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. *Magn Reson Med* 1990;14:154–9.
- Miller DH, Austin SJ, Connolly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. *Lancet* 1991;337:58–9.
- Husted CA, Goodin S, Hugg JW, Maudsley A, Tsuruda JS, de Brie SH. Biochemical alterations in multiple sclerosis lesions and normal appearing white matter detected by in vivo ³¹P and ¹H spectroscopic imaging. *Ann Neurol* 1994;36:157–65.
- Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, *et al.* Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. *Brain* 1995;118:1583–92.
- Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. *Brain* 1980;103:281–300.
- Thompson AJ, Hutchinson M, Brazil J, Martin EA. A clinical and laboratory study of multiple sclerosis. *Q J Med* 1986;58:69–80.
- Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacMannus DG, *et al.* Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. *Neurology* 1993;43:2632–7.
- Arnold DL, Matthews PM, Francis GS, O'Connor, Antel J. Proton magnetic resonance spectroscopic imaging for metabolic characterisation of demyelinating plaques. *Ann Neurol* 1992;31:235–41.
- Phadke JG, Best PV. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. *J Neurol Neurosurg Psychiatry* 1983;46:414–20.
- Rao SM, Leo GJ, Houghton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. *Neurology* 1989;39:161–6.
- Feinstein A, Ron M, Thompson AJ. A serial study of psychometric and MRI changes in multiple sclerosis. *Brain* 1993;116:569–602.
- De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. *Ann Neurol* 1995;38:901–9.
- Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, *et al.* Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. *Brain* 1994;117:49–58.
- Allen IV. Pathology of multiple sclerosis. In: Matthews WB, Compston A, Allen IV, Martyn CM, eds. *McAlpine's multiple sclerosis*. 2nd ed. Edinburgh: Churchill Livingstone, 1991:341–78.
- Davies SEC, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. *J Neurochem* 1995;64:742–8.
- IFBN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. *Neurology* 1993;43:655–61. Comment in: *Neurology* 1993;43:641–3.
- Paty DW, Oger JFF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, *et al.* MRI in the diagnosis of MS: a prospective study and comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. *Neurology* 1988;38:180–4.